article

Self-delivering RNAi: paving the way for a new class of cancer immunotherapies

Posted: 4 December 2018 | | No comments yet

Earlier this year, the National Cancer Institute published its annual report to the nation on the status of cancer stating that there will be nearly 1.8 million new cases of cancer in 2018.1 New therapies have developed over time to improve cancer patient outcomes, including antibody immunotherapies targeting immune checkpoints, such as PD-1. An example is KEYTRUDA® (pembrolizumab), which came to the market in 2014 to treat solid tumours.2 Immunotherapy is rapidly becoming a powerful tool available to physicians and patients to attack cancer with fewer side effects than traditional standard treatments such as surgery, radiotherapy and chemotherapy.3











To read this article in full, please complete the form below. By clicking submit you confirm that you accept our terms and conditions and privacy policy.


*

*

*

*

*

*

*

This content is provided to you for free thanks to the kind support of our sponsors: Agilent

Send this to a friend